Global Drug Delivery Market – Trends and Forecast to 2022
Report Code: HC-R-17-02-DB-175.

Global Drug Delivery Devices Market is expected to reach USD 1,625.1 billion by 2022, at a CAGR of 8.0% during the forecast period of 2016 to 2022. The report contains 775 pages of exclusive premium insights with 1095 tables and 65 figures.

Drug delivery is a process of introducing a therapeutic effect in the human body by administering a pharmaceutical drug at a specific targeted site. Drug delivery system improves the efficacy and safety of drug by controlling the rate, time and release of drug in the body. The drug delivery market is segmented on the basis of route of administration, end users, and region.

Buy Now


Clear selection

"Get Notified On all out New and Upcoming Reports"

       on all the latest research reports

Global Drug Delivery Devices Market is expected to reach USD 1,625.1 billion by 2022, at a CAGR of 8.0% during the forecast period of 2016 to 2022. The report contains 775 pages of exclusive premium insights with 1095 tables and 65 figures.

Drug delivery is a process of introducing a therapeutic effect in the human body by administering a pharmaceutical drug at a specific targeted site. Drug delivery system improves the efficacy and safety of drug by controlling the rate, time and release of drug in the body. The drug delivery market is segmented on the basis of route of administration, end users, and region.

Title

Pages

Price

Cart

BUY FULL REPORT

775

$4200

Buy-Now

Table of Contents

1 INTRODUCTION

1.1. OVERVIEW OF THE DRUG DELIVERY DEVICES MARKET

1.2. CURRENCY AND PRICING

1.3. LIMITATION

1.4. MARKETS COVERED

2 RESEARCH METHODOLOGY

2.1. MARKETS IN DRUG DELIVERY DEVICES MARKET

2.2. GEOGRAPHICAL SCOPE

2.3. YEARS CONSIDERED IN THE STUDY

2.4. CURRENCY AND PRICING

2.5. RESEARCH METHODOLOGY

2.5.1.  MARKET CRACKDOWN APPROACH

2.5.2.  COMPANY REVENUE AND MARKET SHARE ANALYSIS

2.5.3.  DATA TRIANGULATION

2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.7. SECONDARY SOURCES

2.8. ASSUMPTIONS

3 MARKET OVERVIEW

4 EXECUTIVE SUMMARY

5 PREMIUM INSIGHTS

6 DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE

6.1. OVERVIEW

6.2. ORAL DRUG DELIVERY, BY FORM

6.2.1.  SOLID ORAL DRUGS, BY PRODUCT TYPE

6.2.2.1.  TABLETS

6.2.2.2.  CAPSULES

6.2.2.3.  POWDER

6.2.2.4.  PILLS

6.2.2.  LIQUID ORAL DRUGS, BY PRODUCT TYPE

6.2.2.1.  SOLUTIONS

6.2.2.2.  SYRUPS

6.2.2.  SEMI SOLID ORAL DRUGS, BY PRODUCT TYPE

6.2.2.1.  GELS

6.2.2.2.  EMULSIONS

6.2.2.3.  ELIXIRS

6.3. PULMONARY DRUG DELIVERY, BY PRODUCT TYPE

6.3.1.  METERED DOSE INHALERS (MDI)

6.3.2.  DRY POWDER INHALERS (DPI)

6.3.3.  NEBULIZERS

6.3.3.1.  JET NEBULIZERS

6.3.3.2.  ULTRASONIC NEBULIZERS

6.3.3.3.  SOFT MIST NEBULIZERS

6.4. INJECTABLE DRUG DELIVERY, BY PRODUCT TYPE

6.4.1.  INJECTABLE DRUG DELIVERY DEVICES, BY PRODUCT TYPE

6.4.1.1.  CONVENTIONALS INJECTABLES, BY MATERIAL

6.4.1.1.1.  GLASS

6.4.1.1.2.  PLASTIC

6.4.2.2.  CONVENTIONALS INJECTABLES, BY PRODUCT TYPE

6.4.2.2.1.  FILLABLE

6.4.2.2.2.  PRE-FILLED

6.4.3.3.  CONVENTIONALS INJECTABLES, BY USABILITY

6.4.3.3.1.  REUSABLE SYRIGES

6.4.3.3.2.  DISPOSABLE SYRINGES

6.4.3.4.  SELF INJECTION DEVICES

6.4.3.5.  NEEDLE FREE INJECTORS

6.4.3.6.  AUTOINJECTORS

6.4.3.7.  PEN INJECTORS

6.4.3.8.  WEARABLE INJCTORS

6.4.3.9.  OTHERS

6.4.2.  INJECTABLE DRUG DELIVERY FORMULATIONS, BY PRODUCT TYPE

6.4.2.1.  CONVENTIONAL DRUG DELIVERY FORMULATIONS

6.4.2.2.  NOVEL DRUG DELIVERY FORMULATIONS

6.4.2.3.  LONG ACTING INJECTION FORMULATIONS

6.5. OPTHALMIC DRUG DELIVERY, BY PRODUCT TYPE

6.5.1.  OCCULAR DRUG DELIVERY DEVICES, BY PRODUCT TYPE

6.5.1.1.  DRUG COATED CONTACT LENSES

6.5.1.2.  OCCULAR INSERTS

6.5.2.  OCCULAR DRUG DELIVERY FORMULATIONS, BY FORM

6.5.2.1.  LIQUID OCCULAR DRUG DELIVERY FORMULATIONS, BY TYPE

6.5.2.1.1.  EYE DROPS

6.5.2.1.2.  SPRAYS

6.5.2.2.  SEMI-SOLID OCCULAR DRUG DELIVERY FORMULATIONS, BY TYPE

6.5.2.2.1.  GELS

6.5.2.2.2.  OINTMENTS

6.6. NASAL DRUG DELIVERY, BY PRODUCT TYPE

6.6.1.  NASAL DROPS

6.6.2.  NASAL SPRAYS

6.6.3.  NASAL POWDERS

6.6.4.  NASAL GELS

6.7. TOPICAL DRUG DELIVERY, BY PRODUCT TYPE

6.7.1.  TRANSDERMAL DRUG DELIVERY DEVICES, BY PRODUCT TYPE

6.7.1.1.  TRANSDERMAL PATCHES

6.7.1.2.  TRANSDERMAL GELS

6.7.2.  TOPICAL DRUG DELIVERY FORMULATIONS, BY FORM

6.7.2.1.  LIQUID TOPICAL DRUG DELIVERY FORMULATIONS, BY TYPE

6.7.2.1.1.  SOLUTIONS

6.7.2.1.2.  SUSPENSIONS

6.7.2.2.  SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS, BY TYPE

6.7.2.2.1.  GELS

6.7.2.2.2.  CREAMS

6.7.2.2.3.  OINTMENTS

6.7.2.2.4.  PASTES

6.7.2.2.5.  LOTIONS

6.7.2.3.  SOLID TOPICAL DRUG DELIVERY FORMULATIONS, BY TYPE

6.7.2.3.1.  SUPPOSITORIES

6.7.2.3.2.  POWDERS

6.8. IMPLANTABLE DRUG DELIVERY, BY PRODUCT TYPE

6.8.1.  ACTIVE IMPLANTABLE DRUG DELIVERY DEVICES

6.8.2.  PASSIVE IMPLANTABLE DRUG DELIVERY DEVICES

6.9. TRANSMUCOSAL DRUG DELIVERY, BY PRODUCT TYPE

6.9.1.  ORAL TRANSMUCOSAL DRUG DELIVERY, BY TYPE

6.9.1.1.  BUCCAL DRUG DELIVERY

6.9.1.2.  SUBLINGUAL DRUG DELIVERY

6.9.2.  OTHER TRANSMUCOSAL DRUG DELIVERY, BY TYPE

6.9.2.1.  RECTAL TRANSMUCOSAL DRUG DELIVERY

6.9.2.2.  TRANSMUCOSAL TRANSMUCOSAL DRUG DELIVERY

7 DRUG DELIVERY DEVICES MARKET, BY END-USER

7.1. OVERVIEW

7.2. HOSPITALS

7.3. HOME HEALTHCARE

7.4. CLINICS

7.5. COMMUNITY HEALTHCARE

7.6. OTHERS

8 DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL

8.1. OVERVIEW

8.2. HOSPITAL PHARMACIES

8.3. PHARMACY STORES

8.4. DIRECT TENDERS

8.5. ONLINE PHARMACY

9 DRUG DELIVERY DEVICES MARKET, BY GEOGRAPHY

9.1. COUNTRYWISE DRUG DELIVERY DEVICES MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)

9.1.1.      NORTH AMERICA

9.1.1.1.      U.S.

9.1.1.2.      CANADA

9.1.1.3.      MEXICO

9.1.2.      EUROPE

9.1.2.1.      GERMANY

9.1.2.2.      FRANCE

9.1.2.3.      U.K.

9.1.2.4.      ITALY

9.1.2.5.      SPAIN

9.1.2.6.      RUSSIA

9.1.2.7.      TURKEY

9.1.2.8.      BELGIUM

9.1.2.9.      NETHERLANDS

9.1.2.10.      SWITZERLAND

9.1.2.11.    REST OF EUROPE

9.1.3.      ASIA-PACIFIC (APAC)

9.1.3.1.      JAPAN

9.1.3.2.      CHINA

9.1.3.3.      SOUTH KOREA

9.1.3.4.      INDIA

9.1.3.5.      AUSTRALIA

9.1.3.6.      SINGAPORE

9.1.3.7.      THAILAND

Global Drug Delivery Devices Market is expected to reach USD 1,625.1 billion by 2022, at a CAGR of 8.0% during the forecast period of 2016 to 2022. The report contains 775 pages of exclusive premium insights with 1095 tables and 65 figures.

Drug delivery is a process of introducing a therapeutic effect in the human body by administering a pharmaceutical drug at a specific targeted site. Drug delivery system improves the efficacy and safety of drug by controlling the rate, time and release of drug in the body. The drug delivery market is segmented on the basis of route of administration, end users, and region.

The Global Drug Delivery Devices Market have been segmented On the basis of product the market is segmented into oral, injectable, topical, pulmonary, nasal, ocular, implantable and transmucosal. Oral drug is segmented into solid drug, semi-solid drug and liquid drug. The Injectable drug delivery segment is further segmented into devices and formulations. Pulmonary drug delivery segment is further classified into metered dose inhalers (MDI), dry powder inhalers (DPI) and nebulizers. Topical drug delivery segment is segmented based on form into liquid, semi-solid, solid and transdermal. Ocular drug delivery devices are segmented into liquid ocular drugs, semi solid ocular drugs and ocular devices. The implantable drug delivery devices segment includes active and passive implantable drug delivery devices. The transmucosal drug delivery segment is sub segmented into oral transmucosal and others.

Based on end-users the market is segmented into hospitals, over the counter, clinics, home healthcare, community healthcare, and others.

Based on distribution channel the market is segmented into hospital pharmacies, pharmacy stores, direct tenders and online pharmacy.

The global drug delivery devices market is segmented into 5 geographical regions, North America, Europe, Asia-Pacific, South America and rest of the world. These regions are further classified on the basis of country, into 24 major countries such as U.S. Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Belgium, Turkey, Japan, China, Singapore, Brazil, India, Russia, South Africa and many others. The report includes company share analysis for the major companies operating in this market by major regions North America, Europe and Asia Pacific.

 

Major Players Operating in this market:

Bayer AG, Johnson & Johnson, Novartis AG, Pfizer, Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc. , Merck & Co., Sanofi, Antares Pharma, 3M, Becton Dickinson and Company, Nemera, Cima Labs, Inc., Dali Medical Devices, Alkermes, Foamis, Ypsomed, Skyepharma AG, Valeant Pharmaceuticals DSM Biomedical and Catalent, Inc. among others.

 

Regions Covered In The Scope Of The Report:

Global (North America (U.S., Canada, Mexico), Europe (Germany, France, U.K., Italy, Spain, Russia, Belgium, Netherlands, Switzerland, Turkey, Rest of Europe), Asia-Pacific (Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of APAC), South America (Brazil, Rest of South America), Middle East and Africa (South Africa, Rest of MEA))